Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 247.29 |
| Open | 247.21 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1000 |
| Day's Range | 247.24 - 249.55 |
| 52 Week Range | 198.64 - 258.45 |
| Volume | |
| Avg. Volume | 3,042,640 |
| Market Cap | 132.855B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 21.12 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 7.76 (3.12%) |
| Ex-Dividend Date | Aug 17, 2022 |
| 1y Target Est | N/A |
- Business Wire
Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
THOUSAND OAKS, Calif. & CAMBRIDGE, Mass., January 06, 2022--AMGEN & GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT
- GlobeNewswire
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams f
© 2022 Yahoo. All rights reserved.
